2025.01.09
Xi News | Synthetic Fab HuCAL GOLD Library Screening Helps Fizezumab Advance Toward Market Launch
On January 8, 2025, the marketing application for Fasenra, a CD38‑targeting antibody injection developed by Tianjing Biologics, was accepted by the NMPA. This landmark advancement undoubtedly heralds new hope for second‑line treatment of patients with multiple myeloma.
2025.01.05
The commercial development of antibody therapies is a global endeavor, involving tens of thousands of biopharmaceutical companies and supporting service providers. To date, their collective efforts have brought more than 200 antibody therapies to market, with nearly 1,400 additional product candidates in the pipeline currently undergoing clinical evaluation for the treatment of a wide range of diseases.
2025.01.02
STEAP1 belongs to the prostate-specific transmembrane epithelial antigen (STEAP) family, which, in addition to STEAP1, includes STEAP2, STEAP3, and STEAP4. These proteins are involved in numerous biological processes, including apoptosis and cell proliferation, oxidative stress, and the transport of molecules across cellular membranes.
05
2025
/
01
02
2025
/
01
Subscription Information
Subscribe to receive updates from Xichang News.
Shanghai Constream biotechnology Co., Ltd
Phone:021-59255902
Address: Building 2, Floors 2–3, Lane 10688, Beiqing Road, Qingpu District, Shanghai
WeChat Official Account
Copyright © 2026 Shanghai Constream biotechnology Co., Ltd.